Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ZBH
stocks logo

ZBH

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
2.06B
+5.85%
1.986
-1.18%
1.99B
+9.33%
1.817
+4.41%
2.22B
+9.72%
2.345
+1.53%
Estimates Revision
The market is revising Upward the revenue expectations for Zimmer Biomet Holdings, Inc. (ZBH) for FY2025, with the revenue forecasts being adjusted by 0.23% over the past three months. During the same period, the stock price has changed by -2.42%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.31%
In Past 3 Month
Stock Price
Go Down
down Image
-2.42%
In Past 3 Month
21 Analyst Rating
up Image0
Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 107.90 USD with a low forecast of 95.00 USD and a high forecast of 125.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
12 Hold
2 Sell
Hold
up Image0
Current: 97.490
sliders
Low
95.00
Averages
107.90
High
125.00
up Image0
Current: 97.490
sliders
Low
95.00
Averages
107.90
High
125.00
Barclays
Matt Miksic
Sell
Maintains
$118 → $112
2025-02-10
Reason
Barclays
Matt Miksic
Price Target
$118 → $112
2025-02-10
Maintains
Sell
Reason
Barclays lowered the firm's price target on Zimmer Biomet to $112 from $118 and keeps an Underweight rating on the shares. The firm updated its projections to be in-line with Zimmer's 2025 outlook.
Truist Securities
Richard Newitter
Hold
Reiterates
$118 → $113
2025-02-10
Reason
Truist Securities
Richard Newitter
Price Target
$118 → $113
2025-02-10
Reiterates
Hold
Reason
Needham
Mike Matson
Hold
Reiterates
n/a
2025-02-07
Reason
Needham
Mike Matson
Price Target
n/a
2025-02-07
Reiterates
Hold
Reason
JMP Securities
Andrew Boone
Buy
Reiterates
$140
2025-02-07
Reason
JMP Securities
Andrew Boone
Price Target
$140
2025-02-07
Reiterates
Buy
Reason
Raymond James
Jayson Bedford
Buy
Maintains
$126 → $119
2025-02-07
Reason
Raymond James
Jayson Bedford
Price Target
$126 → $119
2025-02-07
Maintains
Buy
Reason
RBC Capital
Shagun Singh
Buy
Maintains
$130 → $125
2025-02-07
Reason
RBC Capital
Shagun Singh
Price Target
$130 → $125
2025-02-07
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Zimmer Biomet Holdings Inc (ZBH.N) is 11.88, compared to its 5-year average forward P/E of 17.06. For a more detailed relative valuation and DCF analysis to assess Zimmer Biomet Holdings Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
17.06
Current PE
11.88
Overvalued PE
20.44
Undervalued PE
13.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
13.00
Current EV/EBITDA
9.11
Overvalued EV/EBITDA
15.06
Undervalued EV/EBITDA
10.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PS
3.46
Current PS
2.26
Overvalued PS
3.94
Undervalued PS
2.99

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 395.76% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

ZBH News & Events

Events Timeline

(ET)
2025-05-05
12:01:09
Zimmer Biomet falls -10.6%
select
2025-05-05
10:00:02
Zimmer Biomet falls -9.1%
select
2025-05-05
09:48:06
Zimmer Biomet falls -6.9%
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
05-08Benzinga
JMP Securities Maintains Market Outperform on Zimmer Biomet Holdings, Lowers Price Target to $125

  • Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

  • Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.

Preview
9.5
05-07Benzinga
These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results

  • Earnings Report: Zimmer Biomet Holdings reported first-quarter adjusted EPS of $1.81, surpassing estimates, with sales of $1.91 billion, reflecting a slight increase from the previous year. The company anticipates adjusted EPS for fiscal year 2025 to be between $7.90 and $8.10, down from earlier guidance.

  • Analyst Ratings: Following the earnings announcement, several analysts maintained their ratings on Zimmer Biomet but lowered their price targets, with notable reductions from firms like Baird, Wells Fargo, and JP Morgan, indicating a cautious outlook despite the company's solid performance.

Preview
6.0
05-07Benzinga
Goldman Sachs Maintains Neutral on Zimmer Biomet Holdings, Lowers Price Target to $104

  • Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

  • Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Zimmer Biomet Holdings Inc (ZBH) stock price today?

The current price of ZBH is 97.49 USD — it has decreased -0.74 % in the last trading day.

arrow icon

What is Zimmer Biomet Holdings Inc (ZBH)'s business?

Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.

arrow icon

What is the price predicton of ZBH Stock?

Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 107.90 USD with a low forecast of 95.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Zimmer Biomet Holdings Inc (ZBH)'s revenue for the last quarter?

Zimmer Biomet Holdings Inc revenue for the last quarter amounts to 1.91B USD, increased 1.05 % YoY.

arrow icon

What is Zimmer Biomet Holdings Inc (ZBH)'s earnings per share (EPS) for the last quarter?

Zimmer Biomet Holdings Inc. EPS for the last quarter amounts to 0.91 USD, increased 8.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Zimmer Biomet Holdings Inc (ZBH)'s fundamentals?

The market is revising Upward the revenue expectations for Zimmer Biomet Holdings, Inc. (ZBH) for FY2025, with the revenue forecasts being adjusted by 0.23% over the past three months. During the same period, the stock price has changed by -2.42%.
arrow icon

How many employees does Zimmer Biomet Holdings Inc (ZBH). have?

Zimmer Biomet Holdings Inc (ZBH) has 18000 emplpoyees as of May 14 2025.

arrow icon

What is Zimmer Biomet Holdings Inc (ZBH) market cap?

Today ZBH has the market capitalization of 19.29B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free